Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic ...

Without providing further context, HHS Secretary Robert F. Kennedy Jr. says that Gavi needs to “start taking vaccine safety ...

Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said the agency’s new risk-based COVID-19 vaccine framework contradicts the ...

Given today’s available local talent pool, biopharma companies are less likely to turn toward international job candidates, ...

Writing in JAMA, four former governmental officials warn that the Trump administration’s involvement in delaying the approval ...

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

Are long R&D cycles, overwhelming literature reviews, or patent bottlenecks slowing your path to innovation? In the ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

Tapping into the hidden job market can be challenging but is important in today’s employer-driven market. Three talent ...

With much to cover, Democrats tackled Kennedy’s MAHA report; the firing of all members of the CDC’s ACIP committee; and much ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...